VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 93 filers reported holding VERVE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $202,449 | -29.2% | 15,279 | +0.2% | 0.00% | – |
| Q2 2023 | $285,881 | +29.7% | 15,255 | -0.2% | 0.00% | – |
| Q1 2023 | $220,424 | -11.8% | 15,286 | +110.3% | 0.00% | – |
| Q3 2022 | $250,000 | -98.4% | 7,268 | -98.9% | 0.00% | -100.0% |
| Q1 2022 | $15,738,000 | -61.8% | 690,011 | -40.7% | 0.01% | -52.9% |
| Q4 2021 | $41,239,000 | -21.4% | 1,162,796 | +0.2% | 0.02% | -26.1% |
| Q3 2021 | $52,478,000 | -34.3% | 1,160,883 | -17.9% | 0.02% | -32.4% |
| Q2 2021 | $79,847,000 | – | 1,413,771 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $28,967,026 | 13.98% |
| Alphabet Inc. | 10,549,086 | $152,117,820 | 8.44% |
| MPM BioImpact LLC | 803,501 | $11,586,484 | 3.01% |
| Casdin Capital, LLC | 2,120,571 | $30,578,634 | 2.52% |
| Novo Holdings A/S | 1,200,000 | $17,304,000 | 1.14% |
| Redmile Group, LLC | 1,120,679 | $16,160,191 | 0.70% |
| Avidity Partners Management LP | 1,351,700 | $19,491,514 | 0.65% |
| ARK Investment Management | 4,482,091 | $64,631,752 | 0.44% |
| BVF INC/IL | 650,000 | $9,373,000 | 0.34% |
| Cormorant Asset Management, LP | 350,000 | $5,047 | 0.33% |